March 16, 2021Open Access

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

SMShabir A. MadhiNational Center for Disease Control VBVicky L. BaillieSouth African Medical Research Council CCClare CutlandUniversity of the Witwatersrand

Key Points

Key points are not available for this paper at this time.

Abstract

A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT04444674; Pan African Clinical Trials Registry number, PACTR202006922165132).

AI से पूछें

Bookmark

View Full Paper